Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Skip to article
Collection contents

Lupus nephritis · For patients · Chapter 8

Treatment safety: a plan, not just a warning list

Infections, vaccines, laboratory monitoring and side effects: how to make treatment safer without losing control of nephritis.

Open access
On this page

A long medication leaflet can make treatment sound like a contest between bad choices. The useful question is more specific: what is this medicine protecting, what problems are we watching for, and what will we do if one appears? Safety monitoring is part of treatment, not evidence that treatment was a mistake.

Before treatment, build a baseline

Your team reviews infections, vaccination history, current medicines, pregnancy plans and relevant test results. Screening may include hepatitis B and C and tuberculosis, depending on the medicine and your circumstances. A previous infection can matter even when you feel completely well. Tell the team about past reactions, repeated infections and infections among close contacts.

Ask for a written monitoring schedule. Blood counts can show whether infection-fighting cells, red cells or platelets are falling. Other tests assess kidney and liver function, electrolytes and urine changes. Different drugs require different checks; an infusion schedule does not automatically cover all necessary laboratory monitoring.

Infection: know whom to contact

Immune-suppressing treatment can increase infection risk. Fever, chills, a new cough, burning urination, painful blisters or a wound that is becoming red and swollen deserve prompt advice. Ask in advance which symptoms require a same-day call and which service answers after hours. Some serious infections cause little fever, so a normal temperature does not cancel concerning symptoms.

Severe breathing difficulty, new confusion, collapse or rapidly worsening illness require emergency assessment. Do not wait for an online message to be answered. See worsening symptoms and urgent action.

Some treatment combinations warrant preventive medicine against particular infections, such as Pneumocystis pneumonia; others do not. Prevention is selected for the individual regimen and risk profile. It is not a reason to take leftover antibiotics.

Vaccines need timing, not a blanket ban

Review influenza, pneumococcal, shingles and other indicated vaccines with your team. Non-live vaccines are often appropriate during treatment, although the immune response can be weaker. Live vaccines need a separate safety assessment and are generally avoided during significant immunosuppression. The timing of B-cell-depleting treatment can particularly affect vaccine responses. Do not stop a medicine or delay an infusion independently to make room for a vaccine; the team should coordinate both.

Examples of live vaccines are MMR, chickenpox, the nasal-spray influenza vaccine and yellow fever; ask before receiving them during immunosuppression. Shingrix is not a live vaccine. CDC recommends it for eligible immunocompromised adults from age 19.

For calcineurin inhibitors, monitoring includes kidney filtration, blood pressure, potassium and interactions. Tacrolimus and cyclosporine usually also require blood drug levels. Voclosporin uses kidney-function monitoring rather than routine trough levels: its US label calls for eGFR checks every two weeks during the first month, every four weeks through year one, then quarterly; your situation may need more frequent review.

Monitoring beyond the blood tests

  • Glucocorticoids can affect sleep, mood, blood pressure, blood sugar and bone health. Report changes; ask about the planned taper and bone protection.
  • Hydroxychloroquine requires retinal screening. Kidney disease, dose and duration influence the monitoring plan; an ordinary glasses check is not the same examination.
  • Mycophenolate can cause gastrointestinal problems and low blood counts, and it requires careful pregnancy prevention and planning.
  • Cyclophosphamide requires discussion of fertility, bladder effects and cumulative exposure, alongside infection and blood-count monitoring.

Make the safety plan usable

Keep one current medication list, including supplements. Ask what to do after a missed dose, vomiting, an infection or a planned procedure. Do not suddenly stop long-term glucocorticoids. Report side effects early: a dose adjustment, a different formulation or additional support may help without abandoning kidney protection. Bring practical problems—cost, transport, nausea, work hours—into the conversation. A regimen that cannot be followed needs attention, not blame.

Sources and further reading

  1. American College of Rheumatology — Vaccination Guideline for Rheumatic and Musculoskeletal Diseases
  2. American College of Rheumatology — Cyclophosphamide
  3. Genentech — CellCept: US Prescribing Information, revised July 2026
  4. American Academy of Ophthalmology — Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy
  5. NHS — Sepsis
  6. CDC — Altered Immunocompetence: Vaccine Guidance
  7. CDC — Shingrix in Immunocompromised Adults Aged 19 Years and Older
  8. DailyMed — Lupkynis (voclosporin): US Prescribing Information
Back to collectionBack to EssentialsFor professionals · English

Rheumatology in Perspective · by Olga Goodman, MD
A RheumaView publication

Evidence checked: 17 October 2026

Educational information. Individual decisions belong with the treating clinical team.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: lupus nephritis